Literature DB >> 2040200

Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study.

J Bahlmann1, K H Schöter, P Scigalla, H J Gurland, M Hilfenhaus, K M Koch, F A Muthny, H H Neumayer, W Pommer, E Quelhorst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2040200     DOI： 10.1159/000419519

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  10 in total

1.  The new FDA labeling for ESA--implications for patients and providers.

Authors:  Braden J Manns; Marcello Tonelli
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-19       Impact factor: 8.237

2.  De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.

Authors:  Bradley A Warady; John Barcia; Nadine Benador; Augustina Jankauskiene; Kurt Olson; Ludmila Podracka; Aleksey Shavkin; Poyyapakkam Srivaths; Cynthia J Wong; Jeffrey Petersen
Journal:  Pediatr Nephrol       Date:  2017-08-17       Impact factor: 3.714

Review 3.  Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?

Authors:  Farhanah Yousaf; Bruce Spinowitz
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

4.  The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Authors:  Junichi Ishigami; Tsuyoshi Onishi; Satomi Shikuma; Wataru Akita; Yoshihiro Mori; Tomoki Asai; Michio Kuwahara; Sei Sasaki; Yusuke Tsukamoto
Journal:  Clin Exp Nephrol       Date:  2012-07-03       Impact factor: 2.801

Review 5.  Erythropoietin: physiology and molecular mechanisms.

Authors:  Robert N Foley
Journal:  Heart Fail Rev       Date:  2008-01-31       Impact factor: 4.214

6.  Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Authors:  Ioannis Koulouridis; Mansour Alfayez; Thomas A Trikalinos; Ethan M Balk; Bertrand L Jaber
Journal:  Am J Kidney Dis       Date:  2012-08-22       Impact factor: 8.860

7.  The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients.

Authors:  Omar Maoujoud; Samir Ahid; Yahia Cherrah
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-02-24

8.  Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial.

Authors:  Valeria Saglimbene; Suetonia C Palmer; Jonathan C Craig; Marinella Ruospo; Antonio Nicolucci; Marcello Tonelli; David Johnson; Giuseppe Lucisano; Gabrielle Williams; Miriam Valentini; Daniela D'Alonzo; Fabio Pellegrini; Paolo Strippoli; Mario Salomone; Antonio Santoro; Stefano Maffei; Jörgen Hegbrant; Gianni Tognoni; Giovanni F M Strippoli
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

9.  Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials.

Authors:  Yuqiu Ye; Hongyong Liu; Yanbing Chen; Yunqiang Zhang; Shaomin Li; Wentao Hu; Rongqian Yang; Zhesi Zhang; Linsheng Lv; Xun Liu
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

Review 10.  Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

Authors:  Suetonia C Palmer; Valeria Saglimbene; Dimitris Mavridis; Georgia Salanti; Jonathan C Craig; Marcello Tonelli; Natasha Wiebe; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.